Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Mar 15, 2007 (Vol. 27, No. 6)

SpringerLink Home-Main

URL:www.springerlink.com/home/main.mpx
  • Abundance of information
  • Nothing significant
SpringerLink, according to the opening page on this site, is “one of the world’s leading interactive databases for high-quality STM journals, book series, books, reference works, and the Online Archives Collection.” The amount of info housed here is not trivial; there are (gulp) over 3 million documents that can be accessed. Full access requires free registration, but even without registering, one can view abstracts and summaries of articles. To be sure, not all of the content is for scientists (for example, architecture, business/economics, humanities), but there is a lot here for biologists/behavioral science (75,000+ articles), biomedical/life sciences (829,000+), chemistry/material sciences (589,000+), earth/environmental science (300,000+), and medicine (650,000+). A site definitely worth a look-see, SpringerLink is packed to the gills.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »